Idiopathic Pulmonary Fibrosis: Drugs
The question
To ask the Secretary of State for Health and Social Care, whether his Department has an estimate of the earliest possible date Jascayd (nerandomilast) could be available to idiopathic pulmonary fibrosis patients.
Answered by Dr Zubir Ahmed
Nerandomilast does not currently have a United Kingdom marketing authorisation for use in the treatment of idiopathic pulmonary fibrosis. It is currently being evaluated by the National Institute for Health and Care Excellence (NICE) which makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS.
Subject to licensing, NICE currently expects to publish final guidance on nerandomilast in September 2026.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →